Date: September 15, 2020
Time: 01:00PM - 02:00PMYou must be registered to participate!
Participants of this webinar will learn about various challenges in cataract surgery and approaches to address such challenges. Additionally, participants will review best practices for billing and coding as well as additional resources that may support greater efficiency of surgical facilities.
OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is the only FDA-approved NSAID-containing intraocular product used in cataract surgery that blocks inflammation to maintain iris tone, prevent miosis, and reduce postoperative pain.
• Provide an overview of the challenges in cataract surgery
• Review best practices for billing and coding by surgical facilities
• Highlight approaches to support greater efficiency and improved outcomes for cataract surgery patients
INDICATIONS AND USAGE
IMPORTANT SAFETY INFORMATION
Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.